Fundraising FoxExactmer
Dagenham, GB · 1 known investors
Find your way into Exactmer
Sign up to see every warm intro you have to Exactmer
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Exactmer team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Exactmer develops organic solvent-stable nanofiltration (OSN) membranes and a liquid-phase synthesis platform for pharmaceutical manufacturers, aimed at lower-cost and more scalable production of oligonucleotide and other advanced polymer therapeutics. It serves drug developers working with chemistries such as ASO, siRNA, peptides, ADC linkers, and PEGs.
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- EXACTMER LIMITED
- Company number
- 11109941
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 13 Dec 2017
- Registered office
- John Eccles House Robert Robinson Avenue, Oxford Science Park, Oxford, OX4 4GP
- Nature of business (SIC)
- 20590 — Manufacture of other chemical products n.e.c.21100 — Manufacture of basic pharmaceutical products32990 — Other manufacturing n.e.c.
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 6 Jul 2026 · next due 20 Jul 2027
Current officers · 3
- Haddleton & Co Limited — corporate secretary, appointed 28 May 2020
- Cristina Bertulli — director, appointed 26 May 2026
- Andrew Guy Livingston — director, appointed 13 Dec 2017
Source: Companies House public register · retrieved 4 Oct 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Exactmer do?
- Exactmer develops organic solvent-stable nanofiltration (OSN) membranes and a liquid-phase synthesis platform for pharmaceutical manufacturers, aimed at lower-cost and more scalable production of oligonucleotide and other advanced polymer therapeutics. It serves drug developers working with chemistries such as ASO, siRNA, peptides, ADC linkers, and PEGs.
- Who are Exactmer's investors?
- Exactmer's investors include Asahi Kasei Corporate Venture Capital.
- Where is Exactmer headquartered?
- Exactmer is headquartered in Dagenham, GB.